Buzz on the Bullboards: Investment Opportunities on the Rise

(Image via Datametrex AI Ltd.)


A busy week for the markets means a busy week for the Stockhouse Bullboards. From sudden investment opportunities to new sector mainstays, we saw a little bit of everything over the last seven days.

First up, here’s a DM for you to slide into ….

Datametrex AI Ltd. (TSXV:DM, Forum) has introduced telemedicine services via their Medi-Call mobile telehealth application.




Over the last few weeks, the team has been working hard to finalize the beta testing of the Medi-Call app with a select group of physicians and end-users.

Highlights:

• The Medi-Call app will be available in English and French initially in the province of BC

• The team will begin expanding geographic coverage over the next several months.

• Beta testing has helped the team achieve a fully functional mobile application that will be available for both Apple iOS and Android

“We are beyond excited to complete our beta testing and start introducing Med-Call to the Canadian market where there is an immediate need for faster access to healthcare,” - Datametrex CEO Marshall Gunter.



Biopharmaceutical company Theratechnologies Inc. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation.

It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of cancer, TH1902, was reported in the update to be progressing well.

The company recently presented new in vivo preclinical data for the TH1902 candidate demonstrating tumour growth inhibition in breast and ovarian cancers. The study examined the efficacy of TH1902 against cancer stem-like cells and its ability to evade some of the known drug resistance phenotypes associated with CSCs.

---

---

Uptake of TH19P01 was exhibited in both cancer stem-like cell lines but was inhibited suggesting that the peptide is highly targeted to protein expression which is absent in healthy cells.

TH1902 induced a marked increase in cell death and produced cell cycle arrest and did not affect healthy tissue. It also significantly inhibited the growth of cancer stem-like cell tumours when administered weekly for three cycles and treated mice exhibited increased tolerability. As a single agent in breast and ovarian cancer stem-like cell xenograft tumour models, TH1902 showed better efficacy as compared to docetaxel alone. Better efficacy was also observed in the ovarian tumour model for the TH1902-carboplatin combination.

An 80% decrease in tumour growth was observed in TH1902. The results demonstrated that TH1902 exerts superior anticancer activity in CD133+ triple-negative breast and ovarian cancer stem-like cell animal models.



Aviation heavyweight Bombardier Inc. (TSX: BBD, Forum) announced that the Challenger 3500 Jet has earned the “Best of the Best” honour from the 2022 Red Dot Award: Product Design.

The Red Dot: Best of the Best is awarded for ground-breaking design and is the highest award in the competition, reserved for the best products in each category.


(Image via Bombardier.)

Bombardier’s President and Chief Executive Officer, Éric Martel said that Bombardier’s design teams are true masters of their craft and I am proud that their work on the Challenger 3500 jet was recognized by the Red Dot jury for belonging to the best in its category

“The Challenger aircraft platform has always delivered impressive performance, consistent reliability and a smooth ride, and I’m thrilled that the new interior design and technological features elevating the aircraft’s cabin experience have been acknowledged by this prestigious award.”

Professor Dr. Peter Zec, founder and CEO of the Red Dot Award commented on the recognition.

“Our jury was especially impressed by the products that won a Red Dot: Best of the Best. This distinction is synonymous with ground-breaking design par excellence. Only a very small percentage of competition winners were awarded this special title because a product needs to have a certain something in order to win this top award. This distinction is proof that Bombardier created a brilliant design!”

For our next Investor Pulse Poll, Stockhouse turns to the recent rise of gold prices. After prices quickly climbed to US $2,000, analysts have been debating where they’ll go from here. We want to hear your voice, so head to the homepage to vote on how high (or low) gold prices will be in the next six months.


(Click image to vote.)


Here are the results of last week's poll ...



Next week on Buzz on the Bullboards we’ll round out the month of April and see how sectors are shaping up during the spring 2022 season. You can catch up on the action right here on the website or subscribe to the newsletter to get the weekly review delivered directly to your mailbox. For previous editions of Buzz on the Bullboards: click here.

---

---

FULL DISCLOSURE: Datametrex AI Ltd. is a client of Stockhouse Publishing.